Related Experiment Video
Updated: Jun 21, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Long-term clinical outcome and left ventricular lead position in cardiac resynchronization therapy
Mads Brix Kronborg1, Andi Eie Albertsen, Jens Cosedis Nielsen
1Department of Cardiology, Aarhus University Hospital, Skejby, Bendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. mads.brix.kronborg@ki.au.dk
Aims:
To identify the predictive value of a presumed optimal left ventricular lead positions (LV-Ps) on the long-term clinical outcome in patients with cardiac resynchronization therapy (CRT).
Methods And Results:
Clinical information was collected from patient files in consecutive patients treated with CRT from 1997 to 2007. A presumed optimal LV-Ps were defined as a position between 2 and 5 o'clock in the short-axis circumference and basal or mid-ventricular in the long axis. Symptomatic response was defined as improvement in NYHA class (>or=1) and echocardiographic response as improvement in left ventricular ejection fraction of >or=5% absolute. We included 567 patients [median age 66 years, 453 (80%) male]. The LV-Ps were optimal in 334 (59%) patients. The hazard ratio for all-cause mortality with an optimal LV-Ps was unadjusted 0.79 (0.59-1.06) and adjusted 0.99 (0.71-1.40). The odds ratio (OR) for symptomatic response with an optimal LV-Ps was unadjusted 1.13 (0.79-1.64) and adjusted 1.05 (0.67-1.64), and the OR for echocardiographic response was unadjusted 1.60 (1.02-2.49) and adjusted 1.42 (0.88-2.31).
Conclusion:
A presumed optimal LV-Ps between 2 and 5 o'clock in the short-axis circumference and basal or mid-ventricular in the long axis is not associated with a lower mortality or a better clinical response in patients treated with CRT.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Cardiomyopathy III: Hypertrophic Cardiomyopathy

